Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F G Foschi

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
ESMO Open|October 8, 2022
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysisM Rimini, L Rimassa, K Ueshima, et al.
Pageof 5